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Abstract: Suitable in vivo and in vitro models are instrumental for the development of new drugs
aimed at improving symptoms or progression of multiple sclerosis (MS). The cuprizone (CPZ)-
induced murine model has gained momentum in recent decades, aiming to address the demyelination
component of the disease. This work aims at assessing the differential cytotoxicity of CPZ in cells of
different types and from different species: human oligodendroglial (HOG), human neuroblastoma
(SH-SY5Y), human glioblastoma (T-98), and mouse microglial (N-9) cell lines. Moreover, the effect
of CPZ was investigated in primary rat brain cells. Cell viability was assayed by oxygen rate
consumption and by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based (MTT)
method. Our results demonstrated that CPZ did not cause death in any of the assayed cell models
but affected mitochondrial function and aerobic cell respiration, thus compromising cell metabolism
in neural cells and neuron-glia co-cultures. In this sense, we found differential vulnerability between
glial cells and neurons as is the case of the CPZ-induced mouse model of MS. In addition, our
findings demonstrated that reduced viability was spontaneous reverted in a time-dependent manner
by treatment discontinuation. This reversible cell-based model may help to further investigate the role
of mitochondria in the disease, and study the molecular intricacies underlying the pathophysiology
of the MS and other demyelinating diseases.
Keywords: neurodegenerative diseases; copper chelator; pathophysiology; cell metabolism; glia
1. Introduction
Multiple sclerosis (MS) is a neurodegenerative, demyelinating, and inflammatory
disease of the central nervous system (CNS) that affects more than 2 million people world-
wide, with a prevalence two to three times higher in women than in men [1]. This disabling
pathology is characterized by the progressive focal loss of oligodendrocytes (OLG) and
myelin membranes around axons, which compromises axonal transport and signal trans-
duction, ultimately leading to progressive worsening of symptoms (reviewed in [2,3]).
The clinical manifestations appear in multiple fully or partially reversible episodes, and
four basic disease courses have been defined and termed as clinically isolated syndrome
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(CIS), relapsing remitting MS (RRMS), secondary progressive MS (SPMS), and primary
progressive MS (PPMS) [4,5]. A myriad of treatments is currently in use in an attempt to
alleviate symptoms or slow down MS progression [4,6–10]. Although some are promising
in early stages of disease, their long-term effects remain uncertain [4,5,11–15].
The convergence of genetic inheritance, hormonal changes, and environmental factors
has long been suspected in determining the risk of developing MS. Despite research
efforts in the last years, the mechanisms underlying the MS pathophysiology are still
unclear [16]. It seems that neurodegenerative processes driven by inflammation-like events
appear at some point in the course of the disease. However, the so-called “inside-out”
model of MS pathogenesis is gaining momentum in recent years [17–19]. Now, the debate
focuses on the exact contribution of each of the mechanisms contributing to axonal damage,
which are not mutually exclusive. Obviously, the advance in understanding cellular and
molecular pathogenic mechanisms of MS is key to develop effective therapies. In total,
three are the main animal models of MS that partially and complementary mimic the
different features of human MS: experimental autoimmune encephalomyelitis (EAE), the
Theiler’s murine encephalomyelitis virus (TMEV) infection-based model, and the toxin-
induced models of demyelination using either cuprizone (CPZ) or lysolecithin [20–22].
The autoimmune models are extensively used in the development of new therapies for
MS, however, when it comes to further studying myelination processes the CPZ-induced
demyelination constitutes the best experimental approach [23–25].
CPZ, bis-cyclohexanone oxaldihydrazone, is a cooper chelator that impacts on the
activity of Cu2+ dependent metalloenzymes such as monoamine oxidase, cytochrome
oxidase or Cu2+/Zn2+-superoxide dismutase. Diverse altered processes, resulting from
enzyme inhibition, compromise energy metabolism and increase oxidative stress [25]. In
the many studies performed with rodents fed with CPZ, acute OLG degeneration and
myelin sheath disruption was followed by spontaneous remyelination after ceasing the
CPZ treatment [22,26]. Nevertheless, it has been shown that the exogenous addition of
Cu2+ does not reduce the CPZ-induced toxicity thus indicating that it is not only acting as
ion chelator and other mechanisms may be sought [27,28]. A major question regarding the
use of CPZ is the molecular mechanism of action by which the toxic induces OLG death
and causes the pathology. To provide reliable answers requires the development of simpler
models, and for this purpose cell lines are instrumental.
This work evaluates the cytotoxicity of CPZ in cell lines and highlights mitochondria
as a key factor in the neurodegeneration associated with MS. The study includes both cell
lines and primary cells.
2. Materials and Methods
2.1. Cell Lines
HOG cell line, established from a surgically removed human oligodendroglioma
by Dr. A. T. Campagnoni (University of California, UCLA, Berkeley, CA, USA) [29]
was kindly provided by Dr. J. A. López-Guerrero (Universidad Autónoma de Madrid,
Madrid, Spain) [30]. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM),
low glucose, pyruvate, HEPES (22320-022, Invitrogen, Paisley, Scotland, UK), 100 units/mL
penicillin and streptomycin (17-602E, Invitrogen, Paisley, Scotland, UK), and 10% (v/v)
heat inactivated fetal bovine serum (FBS) (10270-106, Invitrogen, Paisley, Scotland, UK).
Human neuroblastoma SH-SY5Y cell line was obtained from Sigma (94030304, Sigma-
Aldrich, St. Louis, MO, USA) and was grown in DMEM supplemented with 2 mM L-
glutamine (61965-059, Invitrogen, Paisley, Scotland, UK), 100 units/mL penicillin and
streptomycin (17-602E, Invitrogen, Paisley, Scotland, UK), 1% nonessential amino acids
(11140-035, Invitrogen, Paisley, Scotland, UK), and 10% (v/v) heat inactivated FBS (10270-
106, Invitrogen, Paisley, Scotland, UK).
Human glioblastoma T-98 cell line (ATCC) was grown in Eagle’s Minimum Essential
Medium (EMEM) supplemented with 100 units/mL penicillin and streptomycin (17-602E,
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Invitrogen, Paisley, Scotland, UK), and 10% (v/v) heat inactivated FBS (10270-106, Invitro-
gen, Paisley, Scotland, UK).
Finally, mouse microglial N-9 cells (ATCC) were cultured in Roswell Park Memorial
Institute (RPMI) medium containing 100 units/mL penicillin and streptomycin (17-602E, In-
vitrogen, Paisley, Scotland, UK), and 10% (v/v) heat inactivated FBS (10270-106, Invitrogen,
Paisley, Scotland, UK).
Cells were maintained at 37 ◦C in a humidified atmosphere of 5% CO2 and were
passaged when they were 80–90% confluent, i.e., approximately twice a week for no more
than 20 passages. The experiments were always done with cells from passages 3–15.
2.2. Co-Cultures
HOG and SH-SY5Y cells were co-cultured in a 2:1.5 proportion, respectively, in DMEM
supplemented with 2 mM L-glutamine (61965-059, Invitrogen, Paisley, Scotland, UK),
100 units/mL penicillin and streptomycin (17-602E, Invitrogen, Paisley, Scotland, UK), 1%
nonessential amino acids (11140-035, Invitrogen, Paisley, Scotland, UK), and 10% (v/v)
heat inactivated FBS (10270-106, Invitrogen, Paisley, Scotland, UK). The mixed culture was
grown at 37 ◦C in a humidified atmosphere of 5% CO2 for at least 48 h before the treatments.
2.3. Primary Cultures of Neurons
Cortical neurons were prepared from Sprague–Dawley embryos. Neurons were
isolated as described in [31] and plated at 40,000 cells/0.32 cm2 confluence. Cortical
cells were grown for 12 days in Neurobasal medium (NB) supplemented with 2 mM
L-glutamine, 100 units/mL penicillin and streptomycin, and 2% (v/v) B27 supplement
(Invitrogen, Paisley, Scotland, UK) in a 6-well plate. Animal handling was conducted
at all times in accordance with the European Council Directive 2010/63/UE, as well as
in keeping with current Spanish legislation (RD53/2013). The experimental design was
reviewed and approved by the Ethical Committee for Animal Testing of the University
of Barcelona.
2.4. Cell Treatments
Cell treatments were performed using 3.000–5.000 cells per well in 96-well plates for
MTT reduction assay (MTT is a water-soluble tetrazolium reagent in REDOX reactions
involving mitochondrial components), 40,000 cells per well in 96-well plates for oxygen
consumption assay (OCR), and 30,000 cells per well in 6-well chambered for Trypan blue
exclusion assay (an azo blue dye that selectively colors death cells).
For experiments, a stock solution of 30 mM CPZ (C9012-25G, Sigma-Aldrich, St. Louis,
MO, USA) was prepared freshly. For this, CPZ powder was dissolved in 50% ethanol/
medium shaking at 225 rpm at 60 ◦C for 15–20 min until its complete dissolution. Working
solutions were prepared by diluting the stock in the specific medium for each cell type.
After 24–48 h of plating (30–40% cell confluence), cellular toxicity was induced by the addi-
tion of CPZ in growing concentrations (0.05–1 mM; see corresponding figure legends), for
24, 48, or 72 h. The CPZ concentrations and times of treatments used in these experiments
were based on the bibliography [32,33].
2.5. Oxygen Consumption Rate (OCR) Assay
Oxygen consumption was monitored in oxygen-sensing microplates (Oxoprobics
Biosciences S. L., Madrid, Spain) as described in [34]. The probe is quenched in the
presence of oxygen; as oxygen is consumed by cellular respiration, the fluorescence signal
increases being directly related to cell metabolism [35]. Briefly, cells were seeded in oxygen-
sensing plates and incubated for 24 h (40–50% cell confluence), the different treatments
were added to the cells at the indicated final concentrations, and the wells were sealed
from ambient oxygen by the addition of 100 µL/well of mineral oil. Plates were placed
in a plate reader (Envision, Perkin–Elmer, Waltham, MA, USA) previously equilibrated at
Brain Sci. 2021, 11, 272 4 of 15
37 ◦C and monitored using 340/665 nm excitation/emission filters, with a delay time of
70 µs for 24–48 h.
2.6. MTT Reduction Assay
Cell viability was studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assay, a method based on the activity of mitochondrial NADH-
dependent oxidoreductases as indicator of the functional state of mitochondria, as described
in [34]. After 24–48 h of plating (30–40% cell confluence) and once treatments were com-
pleted, 10 µL of MTT (5 mg/mL in phosphate buffered saline (PBS)) (5655, Sigma-Aldrich,
St. Louis, MO, USA) were added to each well. Then, four hours later, 100 µL of lysis
solution (20% sodium dodecyl sulfate (SDS); 50% dimethylformamide; pH 4) were added
to the culture and incubated overnight at 37 ◦C. Absorbance at 570 nm was measured
using a Multiskan EX Microplate Reader (ThermoFisher Scientific, Waltham, MA, USA).
Values from blank dishes, containing only medium, were subtracted from the values of
the samples. Cell viability, absorbance at 570 nm, was expressed as the percentage of
the controls.
2.7. Trypan Blue Exclusion Assay
The trypan blue exclusion test was used to determine the number of dead cells present
in a cell suspension by an azo dye that only enters cells with altered membranes. After
24–48 h of plating (30–40% cell confluence) and once treatments were completed, cells were
harvested by trypsinization, washed in ice-cold PBS, collected by centrifugation at 200× g
for 5 min, and examined by adding an equivalent volume of a 0.4% trypan blue solution.
The number of live cells (unstained) and dead cells (blue) was counted in a Neubauer
chamber (Laboroptik, Arganda del Rey, Madrid, Spain) under light microscopy, and the
percentage of viable cells was calculated as described in [36]. In total, four samples were
included in each experimental group and each sample was counted at least three times.
2.8. Microscopy Observation
Cell cultures were observed using an inverted and phase contrast Nikon Eclipse TS
100 microscope (Nikon, Minato, Tokyo, Japan) and images were recorded by a digital
Nikon DS-Fi1 camera (Nikon, Minato, Tokyo, Japan).
2.9. Data Analysis
Data result from at least five independent experiments (3–6 replicates). The data in
the graphs are presented as the mean ± S.E.M. Statistical analysis was performed with
SPSS® 18.0 software (IBM, Armonk, NY, USA). The test of Kolmogorov–Smirnov with the
correction of Lilliefors was used to evaluate the fit of the data to a normal distribution and
the test of Levene to evaluate the homogeneity of variance. Significance was analyzed by
one- or two-way ANOVA test followed by post-hoc Tukey’s test for multiple comparisons
as described in [34]. Significant differences were considered when p < 0.05.
3. Results
3.1. Cuprizone Decreases Cell Growth but Does Not Cause Death in HOG Cells
We first investigated the cytotoxic effect of CPZ in the human oligodendroglioma
HOG cell line using human neuroblastoma SH-SY5Y cells as control. Cell viability was
approached by the MTT reduction assay, which is mainly based on reduced activity of
mitochondrial enzymes and electron carriers, i.e., is not, as often considered, a marker for
cell death but of altered energy production. We will use the term cell viability as synonym
of cell having shortage of energy production that if sustained would lead to death. As
shown in Figure 1a–d, CPZ induced a significant loss of signal which was concentration-
dependent manner in both SH-SY5Y and HOG cells and at either 24 or 48 h of treatment.
Data analysis revealed a statistically significant decrease of about 65–70% in cell viability
upon 24 h of treatment with 1 mM CPZ. In cells treated for 48 h the extent of toxicity was
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similar. Importantly, the two cell lines were differentially affected by CPZ, being the OLGs
more sensitive to lower concentrations of the toxic than neurons. In fact, HOG cells were
significantly affected by 0.1–0.5 mM doses of CPZ, while SH-SY5Y cells were more resistant
and higher concentrations (0.5–1.5 mM) were needed to achieve similar effects (Figure 1).
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Figure 1. MTT reduction assay in SH-SY5Y (a,c) and HOG (b,d) cells treated with increasing con-
centrations of CPZ (0.025–1.5 mM) for 24 (a,b) and 48 h (c,d). Cell damage is represented as the
percentage of MTT reduction versus control. Data are the mean ± S.E.M of five independent experi-
ments. Significant differences were analyzed by a one-way ANOVA followed by post-hoc Tukey’s test.
* p < 0.05, ** p < 0.01, *** p < 0.001 compared to control.
To assess whether CPZ-induced decrease in cell viability correlates with an increase in
cell death, a trypan blue exclusion test was p rformed. We found that CPZ, at all tested
concentrations (0.1–1.5 mM), did not caus death in either SH-SY5Y r HOG cell lines fter
24 and 48 h of treatment (Figure 2a–d).
3.2. The Toxic Effect on HOG and SH-SY5Y Cells Is Both Mediated by Mitochondria and Reverted
Once the CPZ Treatment Is Interrupted
As indicated in the introduction section, CPZ-administered mice show a spontaneous
remyelination when the treatment is stopped. To better understand the molecular mecha-
nisms underlying this fact, HOG and SH-SY5Y cells were analyzed after a first treatment
with CPZ (0.2–1.5 mM) for 24 h followed by growth in fresh medium (recovery period).
Results demonstrated the reversion of the toxic effect (60–65%) in both cell lines (Figure 3).
It should be noted that oligodendroglioma cells which are more sensitive to CPZ (see
above) showed better recovery at longer (48 h) times (Figure 3c,d). Our findings suggest
that CPZ affects cell metabolism but that cells recover once the treatment is discontinued.
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three times.
Brain Sci. 2021, 11, 272 7 of 16 
 
 
Figure 3. MTT reduction assay in SH-SY5Y (a,c) and HOG (b,d) cells treated with increasing con-
centrations of CPZ (0.2–1.5 mM) for 24 h followed by 24 (a,b) or 48 h (c,d) without the treatment 
(recovery period). Cell damage is represented as the percentage of MTT reduction versus control. 
Data are the mean ± S.E.M of five independent experiments. Significant differences were analyzed 
by a two-way ANOVA followed by post-hoc Tukey’s test. * p < 0.05, ** p < 0.01, *** p < 0.001 com-
pared to no recovery. 
3.3. Cuprizone Alters Mitochondrial Function but Does Not Cause Death in SH-SY5Y/HOG 
Co-Cultures 
One of the major limitations of the in vitro MS models is that culture of a single cell 
type does not reflect the microenvironment of the CNS. Accordingly, we analyzed the 
cytotoxic effect of CPZ in neuron-glia in vitro model, namely a SH-SY5Y/HOG cell co-
culture. 
First of all, suitable co-culture conditions were determined in terms of optimal 
growth medium and cell type proportion (see Material and Methods section). Apart from 
their morphological identification, we tested by immunofluorescence the presence and 
proportion of both cell types in the co-cultures, specifically using the anti-NeuN antibody 
for SH-SY5Y and the anti-B crystallin antibody for HOG cells (data not shown). In these 
selected conditions, and 24 h after seeding, both cell types were adherent and showed 
small extended processes. At 48 h of co-culture the cells exhibited conical or fusiform bod-
ies and longer processes (Figure 4c,d). Interestingly, we observed that SH-SY5Y and HOG 
cells grew in direct physical contact in a 1:1 ratio, approximately. In fact, cells began to 
establish contacts between them through their extensions at 48 and 72 h of culture (Figure 
4c–f). Moreover, HOG cell processes were longer than those in the monocultures (Figure 
4a,b,d,f). 
Figure 3. MTT reduction assay in SH-SY5Y (a,c) and HOG (b,d) cells treated with increasing con-
centrations of CPZ (0.2–1.5 mM) for 24 h followed by 24 (a,b) or 48 h (c,d) without the treatment
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to no recovery.
Brain Sci. 2021, 11, 272 7 of 15
3.3. Cuprizone Alters Mitochondrial Function but Does Not Cause Death in SH-SY5Y/HOG
Co-Cultures
One of the major limitations of the in vitro MS models is that culture of a single
cell type does not reflect the microenvironment of the CNS. Accordingly, we analyzed
the cytotoxic effect of CPZ in neuron-glia in vitro model, namely a SH-SY5Y/HOG cell
co-culture.
First of all, suitable co-culture conditions were determined in terms of optimal growth
medium and cell type proportion (see Material and Methods section). Apart from their
morphological identification, we tested by immunofluorescence the presence and pro-
portion of both cell types in the co-cultures, specifically using the anti-NeuN antibody
for SH-SY5Y and the anti-B crystallin antibody for HOG cells (data not shown). In these
selected conditions, and 24 h after seeding, both cell types were adherent and showed small
extended processes. At 48 h of co-culture the cells exhibited conical or fusiform bodies and
longer processes (Figure 4c,d). Interestingly, we observed that SH-SY5Y and HOG cells
grew in direct physical contact in a 1:1 ratio, approximately. In fact, cells began to establish
contacts between them through their extensions at 48 and 72 h of culture (Figure 4c–f).
Moreover, HOG cell processes were longer than those in the monocultures (Figure 4a,b,d,f).
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Figure 4. Representative phase contrast inverted microscopy images showing SH-SY5Y (arrowheads)
and HOG cells (arrows) grown in a direct physical contact after 48 (c,d) or 72 h (e,f) of mixed culture.
Cell processes were longer than those in the HOG (a) and SH-SY5Y (b) cells grown separately during
72 h. (a,b,d,f) Scale bars 10 µm (20×); (c,e) Scale bars 10 µm (10×).
As it might be expected, CPZ altered the viability of co-cultures in a concentration-
dependent fashion. Effects were evident at both 24 and 48 h of treatment. Data analysis
revealed a significant decrease (65–70%) in MTT reduction upon 24 h of treatment with
1 mM CPZ (Figure 5a). In cells treated for 48 h the extent of toxicity was similar (Figure 5b).
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reduction versus control. Data are the mean ± S.E.M of five independ t xp riments. Significant
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Finally, we tested whether CPZ-induced decrease in cell viability correlated with
increase in cell death. The trypan blue exclusion test showed that CPZ caused negligible
(5–10%) cell death in SH-SY5Y/HOG co-cultures even at high concentrations (1–1.5 mM)
and irrespective of treatment time (24 or 48 h) (Figure 6).
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Figure 6. The number of SH-SY5Y and HOG living cells in the co-culture was calculated after
treatment with increasing concentrations of CPZ (0.2–1.5 mM) for 24 (a) and 48 h (b). Cell viability
is represented as the percentage of living cells ver us control. Data are the mean ± S.E.M of three
independent experi e t . as run in triplicate, and each plate was counted
at least three times. Significant differences were analyzed by a one-way ANOVA followed by post-hoc
Tukey’s test. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control.
3.4. The Lo s of Cell Viability Caused by Cuprizone in SH-SY5Y/HOG Co-Cultures Is Reverted
Once the Treatment Is Suspended
The next step was to assess the possibility that the loss of cell viability caused by CPZ
could be reverted in SH-SY5Y/HOG co-cultures, as we found for individual cells. Again,
we observed a significant increase in cell viability in co-cultures treated with 0.2–1.5 mM
CPZ for 24 h following by a recovery period (Figure 7). Moreover, the effect was time-
dependent since co-cultures showed greater improvements in viability at 48 than at 24 h of
recuperation (Figure 7). These results are consistent with CPZ reversible actions on cell
metabolism also detectable in neuron-glia co-cultures.
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Figure 7. MTT reduction assay in SH-SY5Y/HOG co-cultures treated with increasing concentra-
tions of CPZ (0.2–1.5 mM) for 24 h followed by 24 (a) o 48 h (b) without the treatment (recovery
period). Cell damage is represented as the percentage of MTT reduction versus control. Data are the
mean ± S.E.M of five independent experiments. Significant differences were analyzed by a two-way
ANOVA followed by post-hoc Tukey’s test. ** p < 0.01, *** p < 0.001 compared to no recovery.
3.5. Oxygen Consumption by the Electron Transport Chain Is Reduced upon CPZ Treatment
To better understand the apparently reversible CPZ effect, we tested the oxygen
consumption rate (OCR) in primary cultures of neurons from rat neuronal cortex. In our
hands, OCR is instrumental to measure the activity of primary cells from white adipose
tissue (WAT) and, therefore, we used them as a control (Figure 8). The decrease in OCR
induced by CPZ was dose-dependent. Notice that oxygen consumption is a kinetic measure
that correlates with the slope of the curves. As shown in Figure 8a,b, the slope was
negligible when either primary WAT or cortical cells were treated with 50 µM CPZ. Then,
a decrease in slope, in OCR and, consequently, in cell respiration, was detected by the
administration of CPZ at concentrations higher than 10 µM (Figure 8). Surprisingly, those
concentrations of CPZ (10 or 50 µM) that did not cause significant reductions in cell viability
were able to significantly reduce oxygen consumption.
These results show that energy metabolism is affected by CPZ in fairly different cell
types (and not only in neural cells). Then, we aimed at comparing OCR data in primary
cultures of neurons with those of glial origin, one from human origin (T-98) with supposedly
mild metabolic activity and another from a rodent glioblastoma (N-9) with supposedly
high metabolic activity. Our findings show that CPZ caused a concentration-dependent
decrease in oxygen consumption in both cell lines (Figure 9). The decline in OCR in T-98
was higher than in the N-9 cells suggesting differential susceptibility to the toxic drug
(Figure 9a). Additionally noticeable is the reduction in respiration rate achieved in the
two glial cell lines by very low concentrations of CPZ. Significant reductions were already
noticed at concentrations as low as 0.1 µM that are ineffective in the case of rat cortical
neurons (Figure 10).
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experiments. RFU: relative fluorescence units.
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4. Discussion 
The use of in vivo and in vitro models is of pivotal relevance in the study of a complex 
disease such as MS, characterized by (i) multifactorial etiology, (ii) inter-individual varia-
bility of clinical manifestations, and (iii) lengthy time-course. In translational research, 
these features and the fact that patient samples can only be obtained post-mortem, pose 
significant limitations [11,37]. Nowadays, promoting an early and strong regeneration 
and remyelination in the CNS appears as the most promising approach in MS treatment, 
and the CPZ mouse model of demyelination seems to be very appropriate [20–22]. Despite 
its advantages, further work is needed to properly ascertain the intracellular pathways 
that lead to neuron damage and OLG apoptotic death. Therefore, it is required a simpler 
model in which molecular mechanism of MS can be better addressed [20,38]. In this sense, 
we here propose a cell model based on in vitro CPZ toxicity that has already been vali-
dated in our laboratory as an effective model to test potential protective molecules that 
could be key in the development of interventions to afford MS-related neuroprotection 
[39]. 
As mentioned, it was difficult to develop MS models in rodents but the CPZ-based 
mice models are of reference now. The dosage necessary to induce demyelination in ro-
dents is strain- and age-dependent. At an appropriate dosage of CPZ the C57BL⁄ 6 genetic 
background leads to (mice) models with CNS lesions that are similar to those found in 
Figure 9. OCR assay in T-98 (a) and N-9 cells (b) incubated with increasing concentrations of CPZ
(0.1–50 µM) for 24 h. Data are the mean ± S.E.M of five independent experiments. Significant
differences were analyzed by a one-way ANOVA followed by post-hoc Tukey’s test. *** p < 0.001
compared to control. RFU: relative fluorescence units.
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4. Discussion
The use of in vivo and in vitro models is of p votal relevance in the study of a com-
plex disease such as MS, characterized by (i) multifactorial etiology, (ii) nter-individual
variabil ty of cli ical man festations, and (iii) lengthy time-course. In translational research,
these features and the fact that patie t sampl s can only be obtained po t-mortem, pose
sign ficant limitations [11,37]. N wadays, promoting an early and strong regeneration and
remyelination in the CNS app ars as the ost promising approach in MS treatment, and
the CPZ mouse mod l of demy linati n seems to be very appropriate [20–22]. Despite its
advantages, further work is needed to properly ascertain the intracellul r pathways that
lead to neuron damage and OLG apoptotic death. Therefore, it is required a simpler model
in which molecular mechanism of MS can be better addressed [20,38]. In this sense, we
here propose a cell model based on in vitro CPZ toxicity that has already been validated in
our laboratory as an effective model to test potential protective molecules that could be
key in the development of interventions to afford MS-related neuroprotection [39].
As mentioned, it was difficult to develop MS models in rodents but the CPZ-based
mice models are of reference now. The dosage necessary to induce demyelination in
rodents is strain- and age-dependent. At an appropriate dosage of CPZ the C57BL⁄ 6
genetic background leads to (mice) models with CNS lesions that are similar to those found
in patients [40]. CPZ as copper ion chelator affects mitochondria and, therefore, we wanted
to assess the effects in different cell lines. Our results show that CPZ alters mitochondrial
function; the compound is mainly toxic for glial cells but it also affects neurons. In fact, the
compound impacts on the functional state of mitochondria and aerobic cell respiration, thus
compromising cell metabolism. There are very few reports that analyze the effect of CPZ in
cellular models. Benetti et al., (2011) observed that treatment with 200 µM of CPZ during 3
weeks did not cause loss of cell viability in SH-SY5Y and GN11 neurons [41]. A later study
revealed that the proliferative and survival rates of SH-SY5Y, microglia, astrocytes, and
OLG precursor cells were not affected by short-term treatment with different concentrations
of CPZ [32]. Recently, it has been demonstrated that CPZ leads to decreases in metabolic
viability in the oligodendroglial cell line, MO3.13 [42]. On the one hand, these discrepancies
in terms of cytotoxicity may be due to the methodology and the concentration or time of
exposure to CPZ. On the other hand, the lack of changes in cell viability, in these previous
studies, may be consequence of the Resazurin reduction test chosen, commercially known
as AlamarBlue®, since it is reported that there are serious concerns about its effectiveness
to assess viability [43–45].
Also noteworthy is that the effect of CPZ does not translate into glial cell death in
contrast to the suggestion derived from in vivo experiments [25]. Demyelinated lesions in
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the brain of CPZ-intoxicated mice are consequence of OLGs death that correlates with mi-
croglial and astroglial activation, and with macrophage accumulation in a highly oxidative
and inflammatory scenario characterized by elevated levels of cytokines [28,42,46,47]. In
this line, our findings suggest that CPZ cell-specific toxicity, by itself, would not be able to
induce OLGs death since immune and inflammatory concomitant cell responses would
be required [20]. So far, no significant loss of neurons in the CPZ-mouse model has been
reported [26], a finding that fits with our results in primary cultures. Interestingly, we also
found that glial cells were more sensitive to CPZ than neurons. OCR results confirm that
CPZ may affect virtually all cell types and that the sensitivity of each cell may depend on
multiple factors; first of all, on the species as indicated by [40] but also on the cell type.
In fact, differential susceptibility of neurons and glia against oxidative or mitochondrial
damage in the aged or diseased brains has been the subject of intensive research [48,49]. In
a very recent study, Luo et al., (2020) demonstrated a differential vulnerability, in terms of
mitochondrial dysfunction, of brain cells of C57BL/6 mice subjected to short-term CPZ
intoxication; the more efficient REDOX system of neurons makes them more resistant
than OLGs to oxidative stress and mitochondrial damage [50]. The results show that CPZ
alters energetic metabolism but why OLGs are more sensitive to these alterations is still an
open question.
One simple approach to partially mimic cell responses that take place in the neuronal–
glia complex networks of the CNS, is the use of mixed cultures [20,51]. Culture of different
cell types in direct contact is useful for some applications but are difficult to obtain, es-
pecially when using primary or 3D cell cultures [20]. In this work, we developed a
SH-SY5Y/HOG cell co-culture to analyze the effects of CPZ treatment in physiological-like
conditions of the CNS. Despite its advantages, there are technical challenges that must be
taken into account when one uses a co-culture of two cell lines, i.e., different nutritional
requirements or growth rate, which complicates measurements of both intra- and inter-
population interactions and makes the results difficult to interpret. Unlike what one might
expect, the effect of CPZ in co-cultures was qualitatively similar to that obtained using
individual cell clones.
The CPZ-induced murine model of demyelination has led to an exponential ad-
vance in testing novel therapies for MS, especially those aimed at addressing the myelin
degenerative aspect of the disease [52]. One of the most relevant conclusions is the spon-
taneous recovery, to our knowledge never attempted using cell lines. Importantly, our
findings demonstrated that the loss of neural viability due to the addition of different
concentrations of the copper chelator was reverted in a time-dependent manner upon
treatment interruption. This result is in line with the reversibility of demyelination af-
ter withdrawal of the toxic in mice subjected for 3–6 weeks to a diet containing 0.2% of
CPZ [53]. Gudi et al., (2014) argued that remyelination phenomenon in murine models is
based on proliferation and differentiation of precursor OLGs [54]. Bearing in mind our
data, we can also hypothesize that mature OLGs functionality is compromised during
treatment but returns back to normal after the toxic challenge.
Despite that CPZ model has constituted, for more than 50 years, one of the best models
for the study of demyelinating diseases such as MS, the exact mechanism of action of CPZ
is not completely understood. Nowadays, the main hypothesis is that CPZ could pass
through biological membranes and compromise mitochondrial function acting directly on
intracellular Cu (II) ion content, affecting Cu2+/Zn2+-superoxide dismutase or monoamine
oxidase function, and diminishing the activity of the electron transport chain [25,54,55].
The consequent decrease in energy production and the increase in oxidative stress lead
to mitochondrial damage and, eventually, to cell death, as it has been shown in vivo in
hepatocytes and also in OLGs [56,57]. In this sense, Pasquini et al., (2007) demonstrated
that CPZ causes the appearance of megamitochondria in OLGs, a large and swollen
dysfunctional form of this subcellular organelle. However, more recently, it has been
suggested that CPZ could also act in an ion chelator independent fashion [27,42,58]. In this
sense, a recent work by Taraboletti and co-workers (2017) indicates that CPZ uptake causes
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lipid metabolism disturbances that compromise OLGs survival. Additionally relevant, is
the proven relationship between CPZ intoxication, oxidative stress and apoptosis in mature
OLGs [25,26,59].
In conclusion, our work demonstrates that CPZ does not cause death in any of the
assayed cell models, albeit it induces a significant loss of metabolic performance, may be
due to the alteration of mitochondrial function, that is spontaneously restored when the
toxic is eliminated. Moreover, we find differential vulnerability between glial cells and
neurons. Therefore, the reversible cytotoxic model here implemented may help to further
investigate the role of mitochondria in MS-associated neurodegeneration. It constitutes,
a suitable approximation to study the interconnected molecular mechanisms underlying
the pathophysiology of the MS and other demyelinating diseases, often characterized by
periods of exacerbation of neurologic symptoms followed by periods of partial or complete
recovery (remissions) as RRMS. Nevertheless, further experimental effort is needed to
address whether the cytotoxicity is mediated by a direct or indirect effect of CPZ on
mitochondrial electron transport chain.
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